CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

In the international, multi-centre trial, the Evolut TAVR demonstrated “continued superior” valve performance, according to ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve ...

holding more than 60% of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards’ SAPIEN ...

In addition, Medtronic shares gained 2.5% on Mar. 31 after the company's positive five-year trial results showed its TAVR device, Evolut, delivered valve performance comparable to surgery ...

Dr. George and the Columbia Valve team discussed new technology from the two largest structural heart companies, the Edwards SAPIEN X4 and the Medtronic Evolut FX. Receive the the latest news, ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...

Furthermore, the launch and European release of the Evolut TAVR system in mid-2020 demonstrated Medtronic’s continued commitment to innovation. The company's consistent dividend payouts bolstered ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...